Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-08-30
2011-08-30
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S141100, C424S145100, C514S001100
Reexamination Certificate
active
08007790
ABSTRACT:
The present invention is directed to methods of treating or ameliorating an effect of a polycystic disease. More particularly, the methods include administering to a patient in need thereof an amount of a modulator of a tumor necrosis factor (TNF) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease. Methods of treating or ameliorating an effect of a polycystic kidney disease (PKD) are also provided. Methods are also provided for identifying a candidate compound that may be effective to treat or ameliorate an effect of a polycystic disease or to increase polycystin-2 (PC2) function or decrease Rab11-Family of Interacting Protein2 (FIP2) function. Further provided are methods for identifying a patient having, or who is at risk for developing, a polycystic disease or who would benefit from treatment with a TNF-alpha inhibitor.
REFERENCES:
patent: 4508703 (1985-04-01), Redziniak et al.
patent: 4621023 (1986-11-01), Redziniak et al.
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5077211 (1991-12-01), Yarosh
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5750495 (1998-05-01), Woo
patent: 5945397 (1999-08-01), Smith et al.
patent: 5981701 (1999-11-01), Wallach et al.
patent: 6015557 (2000-01-01), Tobinick et al.
patent: RE36755 (2000-06-01), Smith et al.
patent: 6271346 (2001-08-01), Hauptmann et al.
patent: 6291646 (2001-09-01), Sledziewski et al.
patent: 6358508 (2002-03-01), Ni et al.
patent: 6379666 (2002-04-01), Tobinick
patent: 6419934 (2002-07-01), Tobinick
patent: 6419944 (2002-07-01), Tobinick
patent: 6423321 (2002-07-01), Tobinick
patent: 6428787 (2002-08-01), Tobinick
patent: 6455040 (2002-09-01), Wei et al.
patent: 6503184 (2003-01-01), Ni et al.
patent: 6537549 (2003-03-01), Tobinick
patent: 6541224 (2003-04-01), Yu et al.
patent: 6638726 (2003-10-01), Wilson et al.
patent: 6689607 (2004-02-01), Ni et al.
patent: 7226593 (2007-06-01), Le et al.
patent: 2001/0021380 (2001-09-01), Pluenneke
patent: 2002/0115080 (2002-08-01), Skouv et al.
patent: 2003/0148264 (2003-08-01), Held et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0182005 (2005-08-01), Tuschl et al.
patent: 2005/0196817 (2005-09-01), Kingsmore et al.
patent: 2005/0267135 (2005-12-01), Escardo et al.
patent: 2005/0282909 (2005-12-01), Diks et al.
patent: 2006/0046961 (2006-03-01), McKay et al.
patent: 2006/0182716 (2006-08-01), Hong et al.
patent: 2006/0275823 (2006-12-01), Kodadek
patent: 2007/0065447 (2007-03-01), Tryggvason et al.
patent: 2007/0259352 (2007-11-01), Bentwich et al.
patent: 2008/0182237 (2008-07-01), Bentwich et al.
patent: WO 91/03553 (1991-03-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 03/048108 (2003-06-01), None
patent: WO 2005/116250 (2005-12-01), None
patent: WO 2006/126040 (2006-11-01), None
Biomed Valley Discoveries, Polycystic Kidney Disease, Enbrel Repurposing Project, pp. 1-13 (2010).
Bhunia et al., “PKD1 Induces p21waf1 and Regulation of the Cell Cycle Via Direct Activation of the JAK-STAT Signaling Pathway in a Process Requiring PKD2,” Cell, vol. 109, pp. 157-168 (2002).
Li et al., “Polycystin-1 and Polycystin-2 Regulate the Cell Cycle Through the Helix-Loop-Helix Inhibitor Id2,” Nature Cell Biology, vol. 7, No. 12, pp. 1102-1112 (2005).
Nagao et al., “Renal Activation of Extracellular Signal-Regulated Kinase in Rats With Autosomal-Dominant Polycystic Kidney Disease,” Kidney Int., vol. 63, pp. 427-437 (2003).
Nauli et al., “Polycystins 1 and 2 Mediate Mechanosensation in the Primary Cilium of Kidney Cells,” Nature Genetics, vol. 33, pp. 129-137 (2003).
Wilson et al., “Cystic Disease of the Kidney,” Annu. Rev. Pathol., vol. 2, pp. 341-368 (2007).
Aguiari et al., “Deficiency of Polycystin-2 Reduces Ca2+ Channel Activity and Cell Proliferation in ADPKD Lymphoblastoid Cells ,” FASB J., vol. 18, pp. 884-886 (2004).
Blind et al., “Cytoplasmic RNA Modulators of an Inside-Out Signal-Transduction Cascade,” Proc. Natl. Acad. Sci. USA, vol. 96, pp. 3606-3610 (1999).
Brody et al., “Aptamers As Therapeutic and Diagnostic Agents,” Reviews in Molecular Biotechnology, vol. 74, pp. 5-13 (2000).
Bugg et al., “Drugs by Design: Structure-Based Design, An Innovative Approach to Developing Drugs, Has Recently Spawned Many Promising Therapeutic Agents, Including Several Now in Human Trials for Treating AIDS, Cancer and Other Diseases,” Sci. Am., vol. 269, pp. 92-98 (1993).
Burger et al., “Drug Screening Using Cell Lines: Cell Supply, High-Throughput and High-Content Assays,” Drug Testing in Vitro: Breakthroughs and Trends in Cell Culture Technology, Marx and Sandig eds., Wiley-VCH, Chapter 5, pp. 127-151 (2007).
Cano et al., “orpk Mouse Model of Polycystic Kidney Disease Reveals Essential Role of Primary Cilia in Pancreatic Tissue Organization,” Development and Disease, vol. 131, pp. 3457-3467 (2004).
Casset et al., “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochem. Biophys. Res. Commun., vol. 307(1), pp. 198-205 (2003).
Chauvet et al., “Expression of PKD1 and PKD2 Transcripts and Proteins in Human Embryo and During Normal Kidney Development,” Am. J. Pathol., vol. 160(3), pp. 973-983 (2002).
Cohen et al., “Structure Design: an Artificial Intelligence-Based Method for the Design of Molecules Under Geometrical Constraints,” J. Mol. Graphics, vol. 11, pp. 166-173 (1993).
Cortez-Retamozo et al., “Efficient Cancer Therapy With a Nanobody-Based Conjugate,” Cancer Res., vol. 64(8), pp. 2853-2857 (2004).
Dean, “Recent Advances in Drug Design Methods: Where Will They Lead?” BioEssays, vol. 16, No. 9, pp. 683-687 (1994).
Enjalbal et al., “Mass Spectrometry in Combinatorial Chemistry,” Mass Spectrom. Rev., vol. 19, pp. 139-161 (2000).
Fassina, “Complementary Peptides As Antibody Mimetics for Protein Purification and Assay,” Immunomethods, vol. 5(2), pp. 121-129 (1994).
Fischer et al., “Protection by Phosphodiesterase Inhibitors Against Endotoxin-Induced Liver Injury in Galactosamine-Sensitized Mice,” Biochem. Pharmacol., vol. 45, No. 12, pp. 2399-2404 (1993).
Gantner et al., “Protection From T Cell-Mediated Murine Liver Failure by Phosphodiesterase Inhibitors,” J. Pharmacol. Exp. Ther., vol. 280, pp. 53-60 (1997).
Genain et al., “Prevention of Autoimmune Demyelination in Non-Human Primates by a cAMP-Specific Phosphodiesterase Inhibitor,” Proc. Natl. Acad. Sci. USA, vol. 92, pp. 3601-3605 (1995).
Hruby, “Conformational and Topographical Considerations in the Design of Biologically Active Peptides,” Biopolymers, vol. 33, pp. 1073-1082 (1993).
Ibraghimov-Beskrovnaya et al., “Polycystin: in Vitro Synthesis, in Vivo Tissue Expression, and Subcellular Localization Identifies a Large Membrane-Associated Protein,” Proc. Natl. Acad. Sci. USA, vol. 94, pp. 6397-6402 (1997).
Krutzfeld et al., “Silencing of MicroRNAs in Vivo With ‘Antagomirs’,” Nature, vol. 438, pp. 685-689 (2005).
Kumar et al., “p38 MAP Kinases: Key Signaling Molecules As Therapeutic Targets for Inflammatory Diseases,” Nat. Rev. Drug Discov., vol. 2(9), pp. 717-726 (2003).
Lee et al., A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis, Nature, vol. 372(6508), pp. 739-746 (1994).
Markowitz et al., “Polycystin-2 Expression Is Developmentally Regulated,” Am. J. Physiol., vol. 277 (1 Pt. 2), pp. F17-F25 (1999).
Marx et al., “Modulation of TNF and GM-CSF Release From Dispersed Human Nasal Polyp Cells and Human Whole Blood by Inhibitors of Different PDE Isoenzymes and Glucocorticoids,” Pul. Pharmacol. & Ther., vol. 15, pp. 7-15 (2002).
Miwatashi et al., “Novel Inhibitor of p38 MAP Kinase As a
Li Rong
Li Xiaogang
Bryan Cave LLP
Lockard Jon M
Saoud Christine J
Stowers Institute for Medical Research
LandOfFree
Methods for treating polycystic kidney disease (PKD) or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating polycystic kidney disease (PKD) or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating polycystic kidney disease (PKD) or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715627